Per the Wall Street Journal, just now -- the snippet, on Januvia® (sitagliptin), from a longer article (do go read it all, there):
. . . .Roche Holding AG said Wednesday an experimental once-weekly treatment under development works better in treating a type of diabetes than Merck's Januvia®, according to a clinical study.
The Basel-based drug company is comparing taspoglutide to Januvia and to a placebo in Phase-III studies on Type 2 diabetes, and said the drug met primary endpoints and was well-tolerated by patients taking it. . . .
For its part, Merck has already issued a statement reaffirming its belief in Januvia. This too should prove interesting -- given the prior FDA warning on pancreatitis risks -- associated with Januvia.
No comments:
Post a Comment